ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Vandortuzumab Biosimilar - Anti-STEAP1 Antibody - BSA and Azide free (A324849)

Recombinant humanized monoclonal antibody to STEAP1 for Flow Cytometry.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 7-10 business days.
Name
Vandortuzumab Biosimilar - Anti-STEAP1 Antibody - BSA and Azide free
Description
Recombinant humanized monoclonal antibody to STEAP1.
Applications
Flow Cytometry
Dilutions
Flow Cytometry: 1:100
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Isotype
IgG1
Conjugate

Unconjugated

Purification
Affinity chromatography.
Concentration
Reconstitution dependent.
Product Form
Lyophilized
Reconstitution
Reconstitute with distilled sterile water.
Formulation
Lyophilized from sterile Phosphate Buffered Saline, pH 7.4. Normally 5%-8% Trehalose is added as protectants before lyophilization.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
General Notes
Prior to reconstitution, centrifuge the vial at 5,000g for 3-5 minutes at room temperature. Reconstitute with appropriate volume of distilled sterile water to bring product to 1mg/ml concentration. After addition of distilled sterile water, mix by gentle tapping. Note: It is not recommended to vortex or vigorously pipette the sample.
Synonyms
PRSS24, Six-transmembrane epithelial antigen of prostate 1, STEAP, STEAP1 protein
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Vandortuzumab Biosimilar - Anti-STEAP1 Antibody - BSA and Azide free (A324849)? Please let us know so that we can list the citation on this page.

Alternative products to Vandortuzumab Biosimilar - Anti-STEAP1 Antibody - BSA and Azide free (A324849)

Proteins predicted to interact with STEAP1

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
97.9% Relevancy Score
75% Relevancy Score
71.7% Relevancy Score
69.9% Relevancy Score
58.9% Relevancy Score
56.8% Relevancy Score
54% Relevancy Score
51.3% Relevancy Score
51.3% Relevancy Score